{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:57:03Z","timestamp":1793048223495,"version":"4.5.0"},"reference-count":194,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"publisher","award":["PDOK-99-23"],"award-info":[{"award-number":["PDOK-99-23"]}],"id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.canlet.2024.217310","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:59:53Z","timestamp":1730422793000},"page":"217310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Clinical challenges in prostate cancer management: Metastatic bone-tropism and the role of circulating tumor cells"],"prefix":"10.1016","volume":"606","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5590-366X","authenticated-orcid":false,"given":"Gayathri K.","family":"Guruvayurappan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Frankenbach-D\u00e9sor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cusan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Aszodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris M.","family":"Holzapfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"B\u00f6cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Mayer-Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2024.217310_bib2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.canlet.2021.11.033","article-title":"The prostate cancer landscape in Europe: current challenges, future opportunities","volume":"526","author":"Marhold","year":"2022","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2024.217310_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.annonc.2020.02.009","article-title":"European cancer mortality predictions for the year 2020 with a focus on prostate cancer","volume":"31","author":"Carioli","year":"2020","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2024.217310_bib5","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/ijc.29538","article-title":"Prevalence of incidental prostate cancer: a systematic review of autopsy studies","volume":"137","author":"Bell","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2024.217310_bib6","unstructured":"Cancer of the Prostate - Cancer Stat Facts,\u201d SEER. Accessed: December. 3, 2023. [Online]. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"\u201cCancer statistics, 2021,\u201d","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.canlet.2024.217310_bib8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cncr.28485","article-title":"No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period","volume":"120","author":"Wu","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.217310_bib9","first-page":"S1","article-title":"Navigating the evolving therapeutic landscape in advanced prostate cancer","volume":"35","author":"Crawford","year":"2017","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.canlet.2024.217310_bib12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(23)00182-1","article-title":"Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments","volume":"24","author":"McIntosh","year":"2023","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrc1528","article-title":"Osteoblasts in prostate cancer metastasis to bone","volume":"5","author":"Logothetis","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.110.077941","article-title":"Prostate cancer: PET with 18 F-fdg, 18 F- or 11 C-acetate, and 18 F- or 11 C-choline","volume":"52","author":"Jadvar","year":"2011","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4103\/0972-3919.119545","article-title":"Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy","volume":"28","author":"Sharma","year":"2013","journal-title":"Indian J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12891-021-03960-z","article-title":"Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario","volume":"22","author":"Brown","year":"2021","journal-title":"BMC Muscoskel. Disord."},{"issue":"2","key":"10.1016\/j.canlet.2024.217310_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: molecular insights and evolving paradigms","volume":"147","author":"Valastyan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.canlet.2024.217310_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/nrc1370","article-title":"Dissecting the metastatic cascade","volume":"4","author":"Pantel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"3421","key":"10.1016\/j.canlet.2024.217310_bib20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"133","author":"Paget","year":"1889","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0002-9440(10)65628-3","article-title":"Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases","volume":"153","author":"Luzzi","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41416-020-01161-4","article-title":"The lingering mysteries of metastatic recurrence in breast cancer","volume":"124","author":"Riggio","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib23","first-page":"333","article-title":"Apoptosis: an early event in metastatic Inefficiency1","volume":"61","author":"Wong","year":"2001","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0002-9440(10)65628-3","article-title":"Multistep nature of metastatic inefficiency : dormancy of solitary cells after successful extravasation and limited survival of early micrometastases","volume":"153","author":"Luzzi","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib25","first-page":"773","article-title":"Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-Iodo-2\u2032 -deoxyuridine23","volume":"45","author":"Fidler","year":"1970","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2024.217310_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2016.02.002","article-title":"Disseminated tumor cells and dormancy in prostate cancer metastasis","volume":"40","author":"van der Toom","year":"2016","journal-title":"Curr. Opin. Biotechnol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/srep36520","article-title":"Axl is required for TGF-\u03b22-induced dormancy of prostate cancer cells in the bone marrow","volume":"6","author":"Yumoto","year":"2016","journal-title":"Sci. Rep."},{"issue":"16_suppl","key":"10.1016\/j.canlet.2024.217310_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5090","article-title":"Recurrence, metastasis, and survival after radical prostatectomy in the era of advanced treatments","volume":"40","author":"Stensland","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2024.217310_bib29","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/1097-0142(19951215)76:12<2530::AID-CNCR2820761219>3.0.CO;2-F","article-title":"Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level","volume":"76","author":"Leibman","year":"1995","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2024.217310_bib30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-08-1754","article-title":"Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence","volume":"15","author":"Morgan","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2024.217310_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158354","article-title":"The use of a new CellCollector to isolate circulating tumor cells from the blood of patients with different stages of prostate cancer and clinical outcomes - a proof-of-concept study","volume":"11","author":"Theil","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.canlet.2024.217310_bib32","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMoa050434","article-title":"A pooled analysis of bone marrow micrometastasis in breast cancer","volume":"353","author":"Braun","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0022-5347(17)38664-0","article-title":"Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate","volume":"142","author":"Hodge","year":"1989","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1464-410X.2010.09876.x","article-title":"The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy","volume":"108","author":"Abdollah","year":"2011","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib35","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2011.04.069","article-title":"Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population","volume":"186","author":"Zaytoun","year":"2011","journal-title":"J. Urol."},{"issue":"17","key":"10.1016\/j.canlet.2024.217310_bib36","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib37","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0022-5347(17)35233-3","article-title":"Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men","volume":"151","author":"Catalona","year":"1994","journal-title":"J. Urol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4103\/1008-682X.125907","article-title":"The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer","volume":"16","author":"Xu","year":"2014","journal-title":"Asian J. Androl."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib39","article-title":"Screening for prostate cancer","author":"Ilic","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.canlet.2024.217310_bib40","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib41","first-page":"94","article-title":"TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression","volume":"4","author":"John","year":"2012","journal-title":"J. Cancer Sci. Ther."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/pcan.2013.50","article-title":"[-2]proPSA is an early marker for prostate cancer aggressiveness","volume":"17","author":"Heidegger","year":"2014","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"9","key":"10.1016\/j.canlet.2024.217310_bib43","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0022-5347(05)66083-1","article-title":"Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies","volume":"166","author":"Stewart","year":"2001","journal-title":"J. Urol."},{"issue":"45","key":"10.1016\/j.canlet.2024.217310_bib45","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/jncimonographs\/lgs031","article-title":"Overdiagnosis of prostate cancer","volume":"2012","author":"Sandhu","year":"2012","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"32","key":"10.1016\/j.canlet.2024.217310_bib46","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.14694\/EdBook_AM.2012.32.98","article-title":"Overdiagnosis and overtreatment of prostate cancer","author":"Thompson","year":"2012","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0046-8177(92)90102-9","article-title":"Early detection of prostate cancer","volume":"23","author":"Scardino","year":"1992","journal-title":"Hum. Pathol."},{"issue":"11","key":"10.1016\/j.canlet.2024.217310_bib48","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"39","author":"Virgo","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib50","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/JU.0000000000001578","article-title":"Therapies for clinically localized prostate cancer: a comparative effectiveness review","volume":"205","author":"Wilt","year":"2021","journal-title":"J. Urol."},{"issue":"11","key":"10.1016\/j.canlet.2024.217310_bib51","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.6004\/jnccn.2018.7060","article-title":"Under-treatment of high-risk localized prostate cancer in the California Latino population","volume":"16","author":"Lichtensztajn","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.12.026","article-title":"Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer","volume":"68","author":"Bratt","year":"2015","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib53","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/JU.0000000000000500","article-title":"Under treatment of prostate cancer in rural locations","volume":"203","author":"Maganty","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2024.217310_bib54","series-title":"National Institute for Health and Care Excellence: Guidelines","article-title":"Prostate cancer: diagnosis and management","year":"2021"},{"issue":"41","key":"10.1016\/j.canlet.2024.217310_bib55","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"7","key":"10.1016\/j.canlet.2024.217310_bib56","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41571-023-00781-y","article-title":"Circulating tumour cells for early detection of clinically relevant cancer","volume":"20","author":"Lawrence","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217310_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216337","article-title":"Longitudinal detection of subcategorized CD44v6+ CTCs and circulating tumor endothelial cells (CTECs) enables novel clinical stratification and improves prognostic prediction of small cell lung cancer: a prospective, multi-center study","volume":"571","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.canlet.2024.217310_bib58","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41571-023-00781-y","article-title":"Circulating tumour cells for early detection of clinically relevant cancer","volume":"20","author":"Lawrence","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2024.217310_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.37871","article-title":"Circulating tumor cell count and overall survival in patients with metastatic hormone-sensitive prostate cancer","volume":"7","author":"Goldkorn","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.canlet.2024.217310_bib60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pbiomolbio.2022.12.005","article-title":"Clinical significance of circulating tumor cell (CTC)-specific microRNA (miRNA) in breast cancer","volume":"177","author":"Wei","year":"2023","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.canlet.2024.217310_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.02.039","article-title":"Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients","volume":"423","author":"Tan","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217310_bib62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canlet.2017.10.004","article-title":"Quantified postsurgical small cell size CTCs and EpCAM+ circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse","volume":"412","author":"Wang","year":"2018","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.canlet.2013.02.015","article-title":"Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs","volume":"335","author":"Fabbri","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217310_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2023.107810","article-title":"Modeling critical interaction for metastasis between circulating tumor cells (CTCs) and platelets adhered to the capillary wall","volume":"242","author":"Milosevic","year":"2023","journal-title":"Comput. Methods Progr. Biomed."},{"issue":"21","key":"10.1016\/j.canlet.2024.217310_bib65","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1158\/1078-0432.CCR-12-2219","article-title":"Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08\/07)","volume":"18","author":"Cathomas","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib66","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/s41467-023-38887-7","article-title":"Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer","volume":"14","author":"Nguyen","year":"2023","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.canlet.2024.217310_bib67","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-13-1550","article-title":"Targeting fibroblast growth factor pathways in prostate cancer","volume":"19","author":"Corn","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"23","key":"10.1016\/j.canlet.2024.217310_bib68","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-20-2306","article-title":"Dual blockade of c-MET and the androgen receptor in metastatic castration-resistant prostate cancer: a phase I study of concurrent enzalutamide and crizotinib","volume":"26","author":"Tripathi","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib69","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","article-title":"Novel therapies emerging in oncology to target the TGF-\u03b2 pathway","volume":"14","author":"Kim","year":"2021","journal-title":"J. Hematol. Oncol.J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.canlet.2024.217310_bib70","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.juro.2008.08.008","article-title":"Effect of IN-1130, a small molecule inhibitor of transforming growth factor-beta type I receptor\/activin receptor-like kinase-5, on prostate cancer cells","volume":"180","author":"Lee","year":"2008","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib71","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbrc.2014.08.154","article-title":"Metformin inhibits epithelial\u2013mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4","volume":"452","author":"Zhang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib72","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s13046-019-1247-3","article-title":"Targeting the SPOCK1-snail\/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis","volume":"38","author":"Chien","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.canlet.2024.217310_bib73","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1158\/1535-7163.MCT-18-0508","article-title":"The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models","volume":"17","author":"Handle","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2024.217310_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101495","article-title":"The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells","volume":"24","author":"Hellsten","year":"2022","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12943-023-01825-8","article-title":"STAT3\/LKB1 controls metastatic prostate cancer by regulating mTORC1\/CREB pathway","volume":"22","author":"Pencik","year":"2023","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib76","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41391-019-0134-5","article-title":"MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer","volume":"22","author":"Nickols","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"9","key":"10.1016\/j.canlet.2024.217310_bib77","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1158\/1535-7163.MCT-10-1033","article-title":"Compensatory pathways induced by MEK inhibition are effective Drug targets for combination therapy against castration-resistant prostate cancer","volume":"10","author":"Gioeli","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"issue":"10295","key":"10.1016\/j.canlet.2024.217310_bib78","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.canlet.2024.217310_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134137","article-title":"Withaferin A induces cell death selectively in androgen-independent prostate cancer cells but not in normal fibroblast cells","volume":"10","author":"Nishikawa","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib80","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10585-021-10093-z","article-title":"Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling","volume":"38","author":"Tanaka","year":"2021","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib81","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13287-020-01773-w","article-title":"Inhibition of Notch pathway enhances the anti-tumor effect of docetaxel in prostate cancer stem-like cells","volume":"11","author":"Wang","year":"2020","journal-title":"Stem Cell Res. Ther."},{"issue":"7","key":"10.1016\/j.canlet.2024.217310_bib82","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1158\/1535-7163.MCT-18-0804","article-title":"Loss of Notch1 activity inhibits prostate cancer growth and metastasis and sensitizes prostate cancer cells to antiandrogen therapies","volume":"18","author":"Rice","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib83","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s13046-019-1342-5","article-title":"The small molecule WNT\/\u03b2-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway","volume":"38","author":"Pak","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.canlet.2024.217310_bib84","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","article-title":"A first-in-human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for wnt ligands, in patients with advanced solid tumors","volume":"23","author":"Jimeno","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.canlet.2024.217310_bib85","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1158\/1535-7163.MCT-22-0216","article-title":"Bioengineered BERA-Wnt5a siRNA targeting Wnt5a\/FZD2 signaling suppresses advanced prostate cancer tumor growth and enhances enzalutamide treatment","volume":"21","author":"Ning","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib86","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1158\/0008-5472.CAN-19-1684","article-title":"Activation of \u03b2-catenin cooperates with loss of pten to drive AR-independent castration-resistant prostate cancer","volume":"80","author":"Patel","year":"2020","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2024.217310_bib87","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1158\/0008-5472.CAN-09-3012","article-title":"Common botanical compounds inhibit the Hedgehog signaling pathway in prostate cancer","volume":"70","author":"\u015alusarz","year":"2010","journal-title":"Cancer Res."},{"issue":"34","key":"10.1016\/j.canlet.2024.217310_bib88","doi-asserted-by":"crossref","first-page":"12561","DOI":"10.1073\/pnas.0404956101","article-title":"Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling","volume":"101","author":"Sanchez","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"15","key":"10.1016\/j.canlet.2024.217310_bib89","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/pros.22517","article-title":"Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b","volume":"72","author":"Karlou","year":"2012","journal-title":"Prostate"},{"issue":"7009","key":"10.1016\/j.canlet.2024.217310_bib90","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature02962","article-title":"Hedgehog signalling in prostate regeneration, neoplasia and metastasis","volume":"431","author":"Karhadkar","year":"2004","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.canlet.2024.217310_bib91","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1634\/theoncologist.2012-314","article-title":"Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer","volume":"18","author":"Antonarakis","year":"2013","journal-title":"Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217310_bib92","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1097-0045(20000501)43:2<77::AID-PROS1>3.0.CO;2-Q","article-title":"Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model","volume":"43","author":"Lein","year":"2000","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib93","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.3892\/ol.2017.5872","article-title":"Angiotensin II receptor blockers induce autophagy in prostate cancer cells","volume":"13","author":"Woo","year":"2017","journal-title":"Oncol. Lett."},{"issue":"11","key":"10.1016\/j.canlet.2024.217310_bib94","doi-asserted-by":"crossref","first-page":"12357","DOI":"10.1021\/acsnano.9b04857","article-title":"Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem","volume":"13","author":"Lang","year":"2019","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib95","doi-asserted-by":"crossref","first-page":"300","DOI":"10.62347\/YPPT5752","article-title":"Experimental treatment efficacy of dmrFABP5 on prostate cancer singly or in combination with drugs in use","volume":"14","author":"Abdulsamad","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217310_bib96","first-page":"3090","article-title":"Rho-associated protein kinase (ROCK) promotes proliferation and migration of PC-3 and DU145 prostate cancer cells by targeting LIM kinase 1 (LIMK1) and matrix metalloproteinase-2 (MMP-2)","volume":"25","author":"Gong","year":"2019","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"issue":"6","key":"10.1016\/j.canlet.2024.217310_bib97","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3892\/or.2014.3491","article-title":"Fasudil inhibits prostate cancer-induced angiogenesis in vitro","volume":"32","author":"Chen","year":"2014","journal-title":"Oncol. Rep."},{"issue":"12","key":"10.1016\/j.canlet.2024.217310_bib98","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.7150\/thno.56604","article-title":"MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib99","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/kjm2.12035","article-title":"Promising effects of pazopanib with radiation on an advanced prostate leiomyosarcoma after failure of systemic chemotherapy","volume":"35","author":"Lin","year":"2019","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.canlet.2024.217310_bib100","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.fob.2015.06.007","article-title":"Small molecules inhibiting the nuclear localization of YAP\/TAZ for chemotherapeutics and chemosensitizers against breast cancers","volume":"5","author":"Oku","year":"2015","journal-title":"FEBS Open Bio"},{"issue":"2","key":"10.1016\/j.canlet.2024.217310_bib101","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jcb.21296","article-title":"Effects of Vitaxin\u00ae, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro","volume":"102","author":"Gramoun","year":"2007","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.canlet.2024.217310_bib102","first-page":"309","article-title":"Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate Carcinoma 1","volume":"60","author":"Livant","year":"2000","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/srep19608","article-title":"Inhibition of lysyl Oxidase and lysyl oxidase-like enzymes has tumour-promoting and tumour-suppressing roles in experimental prostate cancer","volume":"6","author":"Nilsson","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.217310_bib104","doi-asserted-by":"crossref","unstructured":"Activation of BDNF\/TrkB Pathway Promotes Prostate Cancer Progression via Induction of Epithelial\u2010mesenchymal Transition and Anoikis Resistance\u201d, doi: 10.1096\/fj.201802159RRR.","DOI":"10.1096\/fj.201802159RRR"},{"issue":"9","key":"10.1016\/j.canlet.2024.217310_bib105","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1158\/0008-5472.CAN-05-3173","article-title":"Inhibition of the phosphatidylinositol 3\u2032-kinase pathway promotes autocrine fas-induced death of phosphatase and tensin homologue\u2013deficient prostate cancer cells","volume":"66","author":"Bertram","year":"2006","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2024.217310_bib106","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/jcb.22098","article-title":"Magnolol induces apoptosis via inhibiting the EGFR\/PI3K\/Akt signaling pathway in human prostate cancer cells","volume":"106","author":"Lee","year":"2009","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib107","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1002\/cam4.5262","article-title":"Radium\u2010223 dichloride treatment in metastatic castration\u2010resistant prostate cancer in Finland: a real\u2010world evidence multicenter study","volume":"12","author":"Hyv\u00e4kk\u00e4","year":"2022","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib108","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/cells9010032","article-title":"Dual CXCR4 and E-selectin inhibitor, GMI-1359, shows anti-bone metastatic effects and synergizes with docetaxel in prostate cancer cell intraosseous growth","volume":"9","author":"Festuccia","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib109","first-page":"80","article-title":"Silibinin suppresses CD44 expression in prostate cancer cells","volume":"1","author":"Handorean","year":"2009","journal-title":"Am. J. Transl. Res."},{"issue":"7","key":"10.1016\/j.canlet.2024.217310_bib110","doi-asserted-by":"crossref","first-page":"djv085","DOI":"10.1093\/jnci\/djv085","article-title":"Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer","volume":"107","author":"Yates","year":"2015","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2024.217310_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2014.02.299","article-title":"MP24-18 4-METHYLUMBELLIFERONE: dietary supplement turned chemo-preventive and anti-metastatic agent for prostate cancer","author":"Alonzo","year":"2014","journal-title":"J. Urol."},{"issue":"18","key":"10.1016\/j.canlet.2024.217310_bib112","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1158\/0008-5472.CAN-17-0284","article-title":"Proinflammatory CXCL12\u2013CXCR4\/CXCR7 signaling Axis drives myc-induced prostate cancer in obese mice","volume":"77","author":"Saha","year":"2017","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2024.217310_bib113","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1593\/neo.12324","article-title":"CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy","volume":"14","author":"Domanska","year":"2012","journal-title":"Neoplasia"},{"issue":"11","key":"10.1016\/j.canlet.2024.217310_bib114","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/ijc.24665","article-title":"Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs","volume":"125","author":"Pradelli","year":"2009","journal-title":"Int. J. Cancer J. Int. Cancer"},{"issue":"13","key":"10.1016\/j.canlet.2024.217310_bib115","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/pros.24395","article-title":"CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation","volume":"82","author":"Hua","year":"2022","journal-title":"Prostate"},{"issue":"11","key":"10.1016\/j.canlet.2024.217310_bib116","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/sj.bjc.6604064","article-title":"A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV","volume":"97","author":"Steinbild","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"13","key":"10.1016\/j.canlet.2024.217310_bib117","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2004.05.074","article-title":"Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer","volume":"22","author":"Dahut","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2024.217310_bib118","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1200\/JCO.2009.25.4524","article-title":"Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Ning","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib119","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.canlet.2024.217310_bib120","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.canlet.2024.217310_bib121","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1021\/acsbiomaterials.8b01428","article-title":"Biomechanics of collective cell migration in cancer progression: experimental and computational methods","volume":"5","author":"Spatarelu","year":"2019","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib122","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc1075","article-title":"Tumour-cell invasion and migration: diversity and escape mechanisms","volume":"3","author":"Friedl","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.canlet.2024.217310_bib123","doi-asserted-by":"crossref","DOI":"10.1038\/ncb1019","article-title":"Differing modes of tumour cell invasion have distinct requirements for Rho\/ROCK signalling and extracellular proteolysis","volume":"5","author":"Sahai","year":"2003","journal-title":"Nat. Cell Biol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib124","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1083\/jcb.200408028","article-title":"Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP","volume":"167","author":"Sabeh","year":"2004","journal-title":"J. Cell Biol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10585-008-9174-2","article-title":"The actin cytoskeleton in cancer cell motility","volume":"26","author":"Olson","year":"2009","journal-title":"Clin. Exp. Metastasis"},{"issue":"2","key":"10.1016\/j.canlet.2024.217310_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017277","article-title":"Cancer cell invasion is enhanced by applied mechanical stimulation","volume":"6","author":"Menon","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103969","article-title":"Circulating tumor cells: towards mechanical phenotyping of metastasis","volume":"25","author":"Peralta","year":"2022","journal-title":"iScience"},{"issue":"21","key":"10.1016\/j.canlet.2024.217310_bib128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/ijms21218115","article-title":"Fluid shear stress induces EMT of circulating tumor cells via JNK signaling in favor of their survival during hematogenous dissemination","volume":"21","author":"Xin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep39975","article-title":"High shear stresses under exercise condition destroy circulating tumor cells in a microfluidic system","volume":"7","author":"Regmi","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/jnci\/djaa046","article-title":"Physical activity before, during, and after chemotherapy for high-risk breast cancer: relationships with survival","volume":"113","author":"Cannioto","year":"2021","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib131","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1097\/NCC.0000000000000525","article-title":"Physical activity and survival in women with advanced breast cancer","volume":"41","author":"Palesh","year":"2018","journal-title":"Cancer Nurs."},{"issue":"22","key":"10.1016\/j.canlet.2024.217310_bib132","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1158\/0008-5472.CAN-22-0237","article-title":"An exercise-induced metabolic shield in distant organs blocks cancer progression and metastatic dissemination","volume":"82","author":"Sheinboim","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib133","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.devcel.2018.02.015","article-title":"Hemodynamic forces tune the arrest, adhesion, and extravasation of circulating tumor cells","volume":"45","author":"Follain","year":"2018","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2024.217310_bib134","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12943-018-0937-3","article-title":"The functional role of integrins during intra- and extravasation within the metastatic cascade","volume":"18","author":"S\u00f6keland","year":"2019","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.canlet.2024.217310_bib135","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(08)70201-8","article-title":"The \u2018seed and soil\u2019 hypothesis revisited","volume":"9","author":"Fidler","year":"2008","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib136","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12885-015-1409-4","article-title":"Identification of novel drugs to target dormant micrometastases","volume":"15","author":"Hurst","year":"2015","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.canlet.2024.217310_bib137","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/2159-8290.CD-11-0239","article-title":"The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions","volume":"2","author":"Shibue","year":"2012","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.canlet.2024.217310_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158354","article-title":"The use of a new CellCollector to isolate circulating tumor cells from the blood of patients with different stages of prostate cancer and clinical outcomes - a proof-of-concept study","volume":"11","author":"Theil","year":"2016","journal-title":"PLoS One"},{"issue":"9340","key":"10.1016\/j.canlet.2024.217310_bib139","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0140-6736(02)11199-8","article-title":"Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis","volume":"360","author":"Brenner","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib140","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer\u2013specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib141","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/01.ju.0000091876.13656.2e","article-title":"The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy","volume":"170","author":"Ward","year":"2003","journal-title":"J. Urol."},{"issue":"8","key":"10.1016\/j.canlet.2024.217310_bib142","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nrc865","article-title":"Dissemination and growth of cancer cells in metastatic sites","volume":"2","author":"Chambers","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.canlet.2024.217310_bib143","doi-asserted-by":"crossref","first-page":"dmm036236","DOI":"10.1242\/dmm.036236","article-title":"Immune regulation of metastasis: mechanistic insights and therapeutic opportunities","volume":"11","author":"Blomberg","year":"2018","journal-title":"Dis. Model. Mech."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib144","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40425-017-0283-9","article-title":"The immune system in cancer metastasis: friend or foe?","volume":"5","author":"Janssen","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2024.217310_bib145","series-title":"Microcirculation in Cancer Metastasis","author":"Orr","year":"1991"},{"issue":"2","key":"10.1016\/j.canlet.2024.217310_bib146","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2004-02-0434","article-title":"Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis","volume":"104","author":"Camerer","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib147","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","article-title":"Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell\u2013mediated elimination of tumor cells","volume":"105","author":"Palumbo","year":"2005","journal-title":"Blood"},{"issue":"7335","key":"10.1016\/j.canlet.2024.217310_bib148","doi-asserted-by":"crossref","DOI":"10.1038\/nature09707","article-title":"Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL\u2013RANK signalling","volume":"470","author":"Tan","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.canlet.2024.217310_bib149","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-\u03b2: \u2018N1\u2019 versus \u2018N2\u2019 TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.canlet.2024.217310_bib151","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00262-020-02527-6","article-title":"Neutrophils are mediators of metastatic prostate cancer progression in bone","volume":"69","author":"Costanzo-Garvey","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"7069","key":"10.1016\/j.canlet.2024.217310_bib152","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib153","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/embor.2012.41","article-title":"The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cells","volume":"13","author":"Koh","year":"2012","journal-title":"EMBO Rep."},{"issue":"15","key":"10.1016\/j.canlet.2024.217310_bib154","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1158\/1078-0432.CCR-16-0028","article-title":"Cancer tills the premetastatic field: mechanistic basis and clinical implications","volume":"22","author":"Chin","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12964-020-0520-6","article-title":"XIAOPI formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs\/CXCL1 signaling","volume":"18","author":"Zheng","year":"2020","journal-title":"Cell Commun. Signal."},{"issue":"6","key":"10.1016\/j.canlet.2024.217310_bib156","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00262-020-02527-6","article-title":"Neutrophils are mediators of metastatic prostate cancer progression in bone","volume":"69","author":"Costanzo-Garvey","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib157","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","article-title":"Characteristics and significance of the pre-metastatic niche","volume":"30","author":"Liu","year":"2016","journal-title":"Cancer Cell"},{"issue":"7578","key":"10.1016\/j.canlet.2024.217310_bib158","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino","year":"2015","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.canlet.2024.217310_bib159","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4329\/wjr.v7.i8.202","article-title":"Imaging of bone metastasis: an update","volume":"7","author":"O&rsquo","year":"2015","journal-title":"World J. Radiol."},{"key":"10.1016\/j.canlet.2024.217310_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100219","article-title":"Bone metastasis pattern of cancer patients with bone metastasis but no visceral metastasis","volume":"15","author":"Zhu","year":"2019","journal-title":"J. Bone Oncol."},{"issue":"7483","key":"10.1016\/j.canlet.2024.217310_bib161","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"issue":"7473","key":"10.1016\/j.canlet.2024.217310_bib162","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nature12612","article-title":"Arteriolar niches maintain haematopoietic stem cell quiescence","volume":"502","author":"Kunisaki","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib163","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ncb2730","article-title":"Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment","volume":"15","author":"Nombela-Arrieta","year":"2013","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib164","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-5320(81)80116-5","article-title":"Identification of microfilaments in marrow sinus endothelial cells: their possible role in cell egress","volume":"74","author":"Aoki","year":"1981","journal-title":"J. Ultrastruct. Res."},{"issue":"5\u20136","key":"10.1016\/j.canlet.2024.217310_bib165","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/10428199709058305","article-title":"Regulation of hematopoiesis by microvascular endothelium","volume":"27","author":"Rafii","year":"1997","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrc1528","article-title":"Osteoblasts in prostate cancer metastasis to bone","volume":"5","author":"Logothetis","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.canlet.2024.217310_bib167","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41388-018-0540-5","article-title":"Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis","volume":"38","author":"Probert","year":"2019","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.canlet.2024.217310_bib168","doi-asserted-by":"crossref","first-page":"8887","DOI":"10.1158\/0008-5472.CAN-05-1702","article-title":"Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis","volume":"65","author":"Yang","year":"2005","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.canlet.2024.217310_bib169","first-page":"6021","article-title":"Inhibition of transforming growth factor-\u03b2 activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft Model1","volume":"62","author":"Tuxhorn","year":"2002","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.canlet.2024.217310_bib170","first-page":"3298","article-title":"Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft Model1","volume":"62","author":"Tuxhorn","year":"2002","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib171","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2353\/ajpath.2006.050874","article-title":"Cancer interaction with the bone microenvironment","volume":"168","author":"Cher","year":"2006","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib172","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00198-003-1473-5","article-title":"Angiogenesis and marrow stromal cell fates: roles in bone strength","volume":"14","author":"Towler","year":"2003","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.canlet.2024.217310_bib173","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1158\/0008-5472.CAN-04-3448","article-title":"Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway","volume":"65","author":"Huang","year":"2005","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.canlet.2024.217310_bib174","doi-asserted-by":"crossref","first-page":"9108","DOI":"10.1158\/0008-5472.CAN-06-1996","article-title":"\u03b22-Microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis","volume":"66","author":"Huang","year":"2006","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.canlet.2024.217310_bib175","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/cells11244081","article-title":"SFRP2 overexpression induces an osteoblast-like phenotype in prostate cancer cells","volume":"11","author":"Akova \u00d6lken","year":"2022","journal-title":"Cells"},{"issue":"19","key":"10.1016\/j.canlet.2024.217310_bib176","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1158\/0008-5472.CAN-22-0419","article-title":"Mechanoregulation of metastasis beyond the matrix","volume":"82","author":"Er","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217310_bib177","doi-asserted-by":"crossref","DOI":"10.1148\/radiology.178.1.1984305","article-title":"Biologic aggressiveness of palpable and nonpalpable prostate cancer: assessment with endosonography","author":"Baran","year":"1991","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib178","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.urology.2010.02.025","article-title":"Mechanical property characterization of prostate cancer using a minimally motorized indenter in an ex vivo indentation experiment","volume":"76","author":"Ahn","year":"2010","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.canlet.2024.217310_bib179","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/016173469802000403","article-title":"Elastic moduli of breast and prostate tissues under compression","volume":"20","author":"Krouskop","year":"1998","journal-title":"Ultrason. Imag."},{"issue":"5","key":"10.1016\/j.canlet.2024.217310_bib180","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s00330-016-4534-9","article-title":"Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: a preliminary study","volume":"27","author":"Rouvi\u00e8re","year":"2017","journal-title":"Eur. Radiol."},{"issue":"1097","key":"10.1016\/j.canlet.2024.217310_bib181","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180970","article-title":"Stiffness of prostate gland measured by transrectal real-time shear wave elastography for detection of prostate cancer: a feasibility study","volume":"92","author":"Ji","year":"2019","journal-title":"Br. J. Radiol."},{"issue":"16","key":"10.1016\/j.canlet.2024.217310_bib182","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/pros.24617","article-title":"Nanomechanical-based classification of prostate tumor using atomic force microscopy","volume":"83","author":"Zeng","year":"2023","journal-title":"Prostate"},{"issue":"11","key":"10.1016\/j.canlet.2024.217310_bib183","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1039\/b803355b","article-title":"Measurement of elastic properties of prostate cancer cells using AFM","volume":"133","author":"Faria","year":"2008","journal-title":"Analyst"},{"issue":"2","key":"10.1016\/j.canlet.2024.217310_bib184","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.bbrc.2010.10.034","article-title":"Effect of collagen I and fibronectin on the adhesion, elasticity and cytoskeletal organization of prostate cancer cells","volume":"402","author":"Docheva","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2024.217310_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108718","article-title":"In search of the correlation between nanomechanical and biomolecular properties of prostate cancer cells with different metastatic potential","volume":"697","author":"Pogoda","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.canlet.2024.217310_bib186","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.devcel.2020.10.011","article-title":"Mechanical adaptability of tumor cells in metastasis","volume":"56","author":"Gensbittel","year":"2021","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2024.217310_bib187","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jmbbm.2015.06.023","article-title":"Mechanics of intact bone marrow","volume":"50","author":"Jansen","year":"2015","journal-title":"J. Mech. Behav. Biomed. Mater."},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib188","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jmri.21072","article-title":"Age, gender, and skeletal variation in bone marrow composition: a preliminary study at 3.0Tesla","volume":"26","author":"Liney","year":"2007","journal-title":"J. Magn. Reson. Imag."},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib189","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1148\/radiology.175.1.2315484","article-title":"Red and yellow marrow in the femur: age-related changes in appearance at MR imaging","volume":"175","author":"Moore","year":"1990","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1148\/radiology.177.1.2399343","article-title":"Normal age-related patterns of cellular and fatty bone marrow distribution in the axial skeleton: MR imaging study","volume":"177","author":"Ricci","year":"1990","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.canlet.2024.217310_bib191","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ccr.2005.08.010","article-title":"Tensional homeostasis and the malignant phenotype","volume":"8","author":"Paszek","year":"2005","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.canlet.2024.217310_bib192","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1741-7015-4-38","article-title":"Collagen reorganization at the tumor-stromal interface facilitates local invasion","volume":"4","author":"Provenzano","year":"2006","journal-title":"BMC Med."},{"issue":"6824","key":"10.1016\/j.canlet.2024.217310_bib193","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/35065016","article-title":"Involvement of chemokine receptors in breast cancer metastasis","volume":"410","author":"M\u00fcller","year":"2001","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.canlet.2024.217310_bib194","doi-asserted-by":"crossref","first-page":"a036848","DOI":"10.1101\/cshperspect.a036848","article-title":"Bone tropism in cancer metastases","volume":"10","author":"Wang","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:26:03Z","timestamp":1731716763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524007055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":194,"alternative-id":["S0304383524007055"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217310","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical challenges in prostate cancer management: Metastatic bone-tropism and the role of circulating tumor cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217310"}}